Pharmaceuticals Analysts, along with Dr. Raymond Wang, discuss Zevra Therapeutics (ZVRA)’ FDA approved Miplyffa, treatment for Niemann-Pick Disease Type C (NPC) on an Analyst/Industry conference call to be held on November 21 at 12 pm.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZVRA: